Elk Creek Partners Acquired Stake in Cerus Corp

February 14, 2018 - By Adrian Mccoy

 Elk Creek Partners Acquired Stake in Cerus Corp

Investors sentiment increased to 1.32 in Q3 2017. Its up 0.02, from 1.3 in 2017Q2. It improved, as 9 investors sold Cerus Corporation shares while 22 reduced holdings. 11 funds opened positions while 30 raised stakes. 57.26 million shares or 0.28% less from 57.42 million shares in 2017Q2 were reported.

Swiss Bankshares stated it has 0% in Cerus Corporation (NASDAQ:CERS). 58,916 are held by Nationwide Fund Advisors. D E Shaw Inc owns 0% invested in Cerus Corporation (NASDAQ:CERS) for 474,198 shares. Citigroup invested in 1,359 shares. Bank Of America De accumulated 0% or 556,995 shares. Vanguard Group Incorporated accumulated 4.94 million shares or 0% of the stock. Ubs Asset Management Americas owns 49,607 shares. State Board Of Administration Of Florida Retirement System owns 36,846 shares or 0% of their US portfolio. 1.08M were accumulated by First Midwest Bancshares Division. Grp One Trading L P holds 77,583 shares or 0% of its portfolio. Sg Americas Secs Ltd Limited Liability Company stated it has 0% in Cerus Corporation (NASDAQ:CERS). Us Bankshares De owns 0% invested in Cerus Corporation (NASDAQ:CERS) for 38,362 shares. Schwab Charles Invest Mgmt Incorporated stated it has 401,735 shares. Envestnet Asset Mngmt has 5,377 shares for 0% of their portfolio. Art Advisors Llc owns 90,269 shares.

The New Elk Creek Partners Holding in Cerus Corp

Elk Creek Partners reported SC 13G/A form with the SEC for Cerus Corp. Access it here: 000108514618000676. As reported by Elk Creek Partners, the filler owns 5.74% or 6,547,378 shares of the Health Care–company.

Cerus Corp stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Elk Creek Partners’s positive view for Cerus Corp. For a institutional investor managing $800.79 million in assets and having 8+ experts this is interesting position.

Cerus Corp Institutional Sentiment

Filings show 114 investors own Cerus Corp. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 7774655. 73422043 were owned by these investors. 19 funds opened new Cerus Corp stakes, 42 increased positions. There were 14 that closed positions and 32 reduced them.

Birchview Capital Lp is an investor bullish on Cerus Corp, owning 83000 shares as of Q3 2015 for 0.23% of its portfolio. Justin John Ferayorni Tamarack Capital Management Llc owns 900000 shares or 0.49% of its portfolio. NY Baker Bros Advisors Lp have 0.57% of its portfolio for 13553275 shares. Further, Lesa Sroufe & Co reported stake worth 2.14% of its portfolio. The CT Bolton Lp owns 88900 shares. Cerus Corp is 0.06% of its portfolio.

Business Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

SEC Form 13G.

Elk Creek Partners website.

Analysts await Cerus Corporation (NASDAQ:CERS) to report earnings on March, 6. They expect $-0.12 earnings per share, up 7.69 % or $0.01 from last year’s $-0.13 per share. After $-0.12 actual earnings per share reported by Cerus Corporation for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

The stock increased 3.90% or $0.15 during the last trading session, reaching $4. About 903,873 shares traded. Cerus Corporation (NASDAQ:CERS) has declined 40.83% since February 14, 2017 and is downtrending. It has underperformed by 57.53% the S&P500.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company has market cap of $497.66 million. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. It currently has negative earnings. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.

Cerus Corporation (NASDAQ:CERS) Ratings Coverage

Among 5 analysts covering Cerus (NASDAQ:CERS), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Cerus has $8 highest and $4.0 lowest target. $5.50’s average target is 37.50% above currents $4 stock price. Cerus had 10 analyst reports since August 11, 2015 according to SRatingsIntel. The company was maintained on Thursday, November 30 by Robert W. Baird. The stock has “Buy” rating by Robert W. Baird on Monday, October 30. The stock of Cerus Corporation (NASDAQ:CERS) has “Buy” rating given on Wednesday, June 7 by Cantor Fitzgerald. The firm has “Buy” rating given on Monday, January 8 by Cantor Fitzgerald. The stock of Cerus Corporation (NASDAQ:CERS) earned “Buy” rating by Robert W. Baird on Wednesday, January 24. The rating was maintained by BTIG Research on Friday, May 26 with “Buy”. The company was downgraded on Tuesday, August 11 by Zacks. The stock of Cerus Corporation (NASDAQ:CERS) has “Buy” rating given on Thursday, October 5 by Cowen & Co. BTIG Research maintained Cerus Corporation (NASDAQ:CERS) rating on Wednesday, August 19. BTIG Research has “Buy” rating and $8 target. The rating was downgraded by Wedbush to “Neutral” on Thursday, December 17.

More news for Cerus Corporation (NASDAQ:CERS) were recently published by: Fool.com, which released: “Here’s Why Cerus Corporation Stock Popped Today” on January 24, 2018. Businesswire.com‘s article titled: “Cerus Reports Positive Top-Line Results from Chronic Anemia Phase 3 Study …” and published on January 23, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: